Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.42 |
| ▸ | GSR | P00390 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL168163 | 0.82 | PTGDR2 (0.54) | ENPP2PTGS2PTGDR2 | |
| Lithium Ion SCHEMBL16341759 | 0.82 | ENPP2 (0.50) | ENPP2PTGS2EPHX2NR1H4PTGDR2 | |
| SCHEMBL8052632 | 0.82 | PTGDR2 (0.54) | ENPP2PTGS2PTGDR2 | |
| SCHEMBL2396163 | 0.82 | ENPP2 (0.50) | ENPP2PTGS2EPHX2NR1H4PTGDR2 | |
| SCHEMBL15682633 | 0.81 | ENPP2 (0.45) | ENPP2PTGS2EPHX2NR1H4PTGDR2 | |
| SCHEMBL3654279 | 0.80 | ENPP2 (0.48) | ENPP2PTGS2EPHX2NR1H4PTGDR2 | |
| SCHEMBL1395792 | 0.80 | CA2 (0.55) | ENPP2 | |
| Hydrochloric Acid SCHEMBL15411526 | 0.80 | PTGDR2 (0.52) | ENPP2PTGS2PTGDR2 | |
| SCHEMBL9300170 | 0.80 | CA2 (0.46) | — | |
| SCHEMBL6839967 | 0.79 | ENPP2 (0.52) | ENPP2PTGS2EPHX2NR1H4PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101120003-B | Thieno-pyridine derivatives as GABA-B allosteric enhancers | HOFFMANN LA ROCHE | 2010-06-16 | — | — | CN | disclosed |
| EP-1828199-B1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | HOFFMANN LA ROCHE (CH) | 2009-05-06 | — | — | EP | disclosed |
| US-7390903-B2 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. (US) | 2008-06-24 | — | — | US | disclosed |
| CN-101120003-A | Thieno-pyridine derivatives as GABA-B allosteric enhancers | HOFFMANN LA ROCHE (CH) | 2008-02-06 | — | — | CN | disclosed |
| EP-1828199-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006063732-A1 | THIENO-PYRIDINE DERIVATIVES AS GABA-B ALLOSTERIC ENHANCERS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135552-A1 | Thieno-pyridine derivatives as allosteric enhancers of the GABAB receptors | GABBR1, CHRNA5, CHRNA3 | ENPP2 1486/4885PTGS2 2749/4885EPHX2 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.